Summaries of the Section H (HML) update

Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.

The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule. 

The changes will be published in the Online HML(external link) around the 23rd of this month and are effective from next month. 

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

16 February 2024 - preview of changes for March 2024

Pharmaceutical

Change

Atomoxetine cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg

Brand change

  • APO-Atomoxetine - price increase and addition of PSS
  • Generic Partners – to be delisted 1 August 2024

Chlorhexidine with cetrimide irrigation soln 0.015% with cetrimide 0.15%, 100 ml bottle

 

  • new listing
  • Baxter – irrigation soln 0.015% with cetrimide 0.15%, 100 ml bottle – delisted 1 March 2024

Clomipramine hydrochloride (Clomipramine Teva) cap 10 mg

new listing (p’code 2674149)

Fluorouracil (Fluorouracil Accord) inj 50 mg per ml, 50 ml vial

new listing (p’code 2674092)

Glycomacropeptide and amino acid contains some phenylalanine (PKU GMPro Ultra Lemonade) powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet

moved chemical to new therapeutic group and revoked delisting

Goserelin (Teva) implant 3.6 mg, syringe and 10.8 mg, syringe

price increase

Hyoscine hydrobromide (Scopoderm TTS) patch 1 mg per 72 hours

amended presentation description

Hyoscine hydrobromide (Scopolamine - Mylan) patch 1 mg per 72 hours – new listing

new listing (p’code 2674181)

Lapatinib tab 250 mg

new listing

Lidocaine [Lignocaine] hydrochloride inj 10%, 5 ml ampoule

new listing

Meningococcal B multicomponent (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe, 10 inj pack

new listing (p’code 2671948)

Methyldopa (Methyldopa Mylan) tab 250 mg*

to be delisted 1 September 2024

* Pharmacodes 2500167 and 2603934

Nivolumab (Opdivo) inj 10 mg per ml, 4 ml vial and 10 ml vial

amended restriction criteria

Olanzapine (Zypine) tab 2.5 mg, 5 mg and 10 mg

Pack size change

  • 30 tab pack – new listing and addition of PSS (p’code 2651076, 2651084 and 2651092 respectfully)
  • 28 tab pack – to be delisted 1 August 2024

Paclitaxel

·        Inj 6 mg per ml, 16.7 ml vial

·       Inj 6 mg per ml, 50 ml vial

Brand change

  • Anzatax – new listing and addition of PSS (p’code 2271834 and 2271818 respectively)
  • Paclitaxel Ebewe 16.7 ml, 25 ml and 50 ml – to be delisted 1 August 2024

Paracetamol (Paracetamol Kabi) inj 10 mg per ml, 100 ml vial

price increase

Pembrolizumab (Keytruda) inj 25 mg per ml, 4 ml vial

amended restriction criteria

Phenobarbitone tab 15 mg

Brand change

  • Noumed Phenobarbitone – new listing and addition of PSS (p’code 2647524)
  • PSM – to be delisted 1 August 2024

Pralidoxime chloride inj 1 g vial

new listing

Sacubitril with valsartan

  • Tab 24.3 mg with valsartan 25.7 mg (Entresto 24/26)
  • Tab 48.6 mg with valsartan 51.4 mg (Entresto 49/51)
  • Tab 97.2 mg with valsartan 102.8 mg (Entresto 97/103)

amended restriction criteria

Simvastatin (Simvastatin Mylan) tab 80 mg

to be delisted 1 September 2024

Timolol eye drops 0.5%, gel forming

new listing

Varicella zoster vaccine [shingles vaccine] (Shingrix) inj 50 mcg per 0.5 ml vial plus vial, 10 inj pack

new listing p’code (2671921)

Vincristine sulphate (DBL Vincristine Sulfate) inj 1 mg per ml, 1 ml vial

price decrease